The FDA has approved Novavax’s COVID-19 vaccine, Nuvavoxid, for use in adults 65 and older and in individuals ages 12-64 who have at least one underlying health condition.
The approval is based on phase 3 clinical trial data that showed that the protein-based vaccine is safe and effective in preventing COVID-19, according to a May 19 news release from Novavax.
However, the FDA is also requiring Novavax to conduct a phase 4 clinical trial in individuals ages 50-64 who do not have high-risk conditions.
Nuvavoxid has been available in the U.S. under emergency use authorization since July 2022, and unlike mRNA vaccines, Nuvavoxid uses a protein-based platform.
Novavax and Sanofi plan to distribute the updated formulation in the fall, pending final strain recommendations from the FDA’s vaccine advisory committee.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
